[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 23.23.54.109. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 486
Citations 0
Comment and Response
August 7, 2013

BRAF V600E Mutation and Papillary Thyroid Cancer—In Reply

Author Affiliations
  • 1Division of Endocrinology, Diabetes, and Metabolism, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
JAMA. 2013;310(5):535-536. doi:10.1001/jama.2013.8595

In Reply We agree with Dr Xing that the analyses presented by Xing et al support an important biological role for BRAF V600E in promoting aggressive tumor behaviors. We disagree with Xing’s interpretation of the multivariable mortality analyses that included BRAF V600E status and PTC tumor behaviors (extrathyroidal invasion, lymph node metastases, and distant metastases) as predictors.

What these multivariable analyses showed was that when the BRAF V600E test result was examined together with aggressive tumor behaviors, BRAF V600E status was no longer independently associated with mortality. This multivariable model replicates the question confronting the clinician: what does knowledge of BRAF V600E status add to existing clinical staging? As we discussed in our Editorial, the analyses by Xing et al suggest that BRAF V600E testing does not contribute to the predictive value for PTC-related mortality beyond the information gleaned about aggressive tumor characteristics reported by a pathologist or radiological evaluation.

First Page Preview View Large
First page PDF preview
First page PDF preview
×